27,077 Shares in Progyny, Inc. $PGNY Bought by Smallwood Wealth Investment Management LLC

Smallwood Wealth Investment Management LLC bought a new position in shares of Progyny, Inc. (NASDAQ:PGNY) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 27,077 shares of the company’s stock, valued at approximately $583,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PGNY. Cetera Trust Company N.A increased its stake in shares of Progyny by 303.1% in the second quarter. Cetera Trust Company N.A now owns 1,310 shares of the company’s stock valued at $29,000 after buying an additional 985 shares during the period. Militia Capital Partners LP boosted its holdings in Progyny by 100.0% in the first quarter. Militia Capital Partners LP now owns 2,000 shares of the company’s stock valued at $45,000 after acquiring an additional 1,000 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in Progyny during the 2nd quarter valued at approximately $77,000. USA Financial Formulas bought a new position in Progyny during the 3rd quarter worth approximately $100,000. Finally, AlphaQuest LLC lifted its position in shares of Progyny by 57.9% in the 1st quarter. AlphaQuest LLC now owns 5,668 shares of the company’s stock worth $127,000 after purchasing an additional 2,079 shares during the period. 94.93% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Wall Street Zen cut shares of Progyny from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Canaccord Genuity Group increased their price target on Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a report on Monday, November 17th. Barclays began coverage on Progyny in a research report on Monday, December 8th. They issued an “overweight” rating and a $29.00 price objective for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Progyny in a research note on Monday, December 22nd. Finally, JPMorgan Chase & Co. lifted their target price on Progyny from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

Progyny Price Performance

Shares of PGNY opened at $25.80 on Friday. Progyny, Inc. has a one year low of $15.71 and a one year high of $27.76. The company has a market cap of $2.22 billion, a PE ratio of 40.95, a P/E/G ratio of 2.03 and a beta of 0.97. The stock has a 50-day moving average of $23.63 and a 200-day moving average of $22.70.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.06. Progyny had a return on equity of 10.71% and a net margin of 4.46%.The business had revenue of $313.35 million for the quarter, compared to the consensus estimate of $299.23 million. During the same period in the prior year, the business earned $0.11 EPS. The firm’s revenue for the quarter was up 9.3% on a year-over-year basis. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. Analysts expect that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Insiders Place Their Bets

In other Progyny news, CFO Mark S. Livingston sold 21,303 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $25.50, for a total value of $543,226.50. Following the transaction, the chief financial officer directly owned 48,358 shares of the company’s stock, valued at approximately $1,233,129. This trade represents a 30.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Peter Anevski acquired 79,500 shares of Progyny stock in a transaction dated Thursday, November 13th. The shares were acquired at an average price of $24.29 per share, with a total value of $1,931,055.00. Following the completion of the acquisition, the chief executive officer directly owned 680,251 shares of the company’s stock, valued at approximately $16,523,296.79. The trade was a 13.23% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders sold 22,046 shares of company stock worth $561,691. 9.40% of the stock is owned by company insiders.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.